In a recent study, researchers from US Department of Energy’s Lawrence Berkeley National Laboratory and the University of California discovered that healthy mammary cells discharge an anti-cancer protein help causing breast cancer cells to self-destruct devoid of distressing other normal cells. The protein they found is known as IL-25 (interleukin-25).
This protein has the most effective anti-cancer activity, amongst all six factors discharged by the breast epithelial cells. The research team after bruising nearly seventy samples of both cancerous and noncancerous breast cells with IL-25 receptor antibodies, observed that the cancerous cells remained blemished, which showed that IL-25 receptors were tumor specific and could be a good indicator of cancerous tissue.
In another study conducted on mice in which fifteen mice with breast tumour, when treated daily with IL-25 showed three times smaller size of tumour, with no side effects, in comparison to those treated with saline placebo treatment. According study author MinaBissell from Berkeley Lab’s Life Sciences Division, they found that normal breast cells provide an inherent defense mechanism against cancer.
They produce IL-25 to aggressively and specifically kill breast cancer cells. This advocates that IL-25 receptor signaling may provide a new therapeutic target for the treatment of breast cancer, she added. The major functions of IL-25 people have studied so far is its role in inflammatory response, explained co-author Saori Furuta, a postdoctoral fellow.
A number of tumor observation methods have been described in the past, counting the classic molecular tumor suppressors, immune surveillance and suppression by the extracellular matrix and other micro-environmental aspects. They are now adding a new type of tumor suppression to this list, IL-25 and other proteins secreted by normal breast cells that kill or suppress their mutated neighbors.
Because IL-25 is generated by healthy breast tissue as a natural defense mechanism against cancer during the cell demarcation process, they should be able to utilize IL-25 and IL-25 receptor signaling as an organic move toward to breast cancer therapy, added Furuta. The finding of the study was published in the journal Science Translational Medicine.